Comparative analysis of stress responses of H9c2 rat cardiomyoblasts following treatment with doxorubicin and tBOOH

Experimental Cell Research

Volumn 318, Issue 6, 2012, Pages 779-788

  Döhrmann, Mareike ^b   Schorr, Anne ^a   Hülsenbeck, Johannes ^b   Rasmussen, Tine L ^c   Issinger, Olaf Georg ^c   Fritz, Gerhard ^a,b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c Institute of Biochemistry and Molecular Biology   (Denmark)

Author keywords

Cardiomyocytes; Doxorubicin; Genotoxic stress response; Protein kinase CK2; Resorufin; ROS

Indexed keywords

ACETYLCYSTEINE; DOXORUBICIN; HISTONE H2AX; REACTIVE OXYGEN METABOLITE; RESORUFIN; STRESS ACTIVATED PROTEIN KINASE; TERT BUTYL HYDROPEROXIDE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARDIOMYOBLAST; CELL CULTURE; CELL CYCLE PROGRESSION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; DRUG MEGADOSE; FLUORESCENCE ACTIVATED CELL SORTING; HEART MUSCLE CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SERUM FACTOR; STRESS; WESTERN BLOTTING;

RATTUS;

EID: 84857651740     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.01.010     Document Type: Article

References (31)

1. Kalender Y., Yel M., Kalender S. Doxorubicin hepatotoxicity and hepatic free radical metabolism in rats. The effects of vitamin E and catechin. Toxicology 2005, 209:39-45.
2. Lyu Y.L., Kerrigan J.E., Lin C.P., Azarova A.M., Tsai Y.C., Ban Y., Liu L.F. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007, 67:8839-8846.
3. Ferreira A.L., Matsubara L.S., Matsubara B.B. Anthracycline-induced cardiotoxicity. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6:278-281.
4. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
5. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54(Suppl. 4):1-7.
6. Yan T., Deng S., Metzger A., Godtel-Armbrust U., Porter A.C., Wojnowski L. Topoisomerase II{alpha}-dependent and -independent apoptotic effects of dexrazoxane and doxorubicin. Mol. Cancer Ther. 2009, 8:1075-1085.
7. Willmore E., Errington F., Tilby M.J., Austin C.A. Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochem. Pharmacol. 2002, 63:1807-1815.
8. Hasinoff B.B., Herman E.H. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?. Cardiovasc. Toxicol. 2007, 7:140-144.
9. van Dalen E.C., Caron H.N., Dickinson H.O., Kremer L.C. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst. Rev. 2008, CD003917.
10. Classen S., Olland S., Berger J.M. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10629-10634.
11. Damrot J., Nuebel T., Epe B., Roos W.P., Kaina B., Fritz G. Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide. Br. J. Pharmacol. 2006, 149:988-997.
12. Huelsenbeck J., Henninger C., Schad A., Lackner K.J., Kaina B., Fritz G. Inhibition of Rac1 signaling by lovastatin protects against anthracycline-induced cardiac toxicity. Cell Death Dis. 2011, 2:e190. 10.1038/cddis.2011.1065.
13. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 2009, 61:154-171.
14. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
15. Niefind K., Raaf J., Issinger O.G. Protein kinase CK2 in health and disease: protein kinase CK2: from structures to insights. Cell. Mol. Life Sci. 2009, 66:1800-1816.
16. Olsen B.B., Guerra B., Niefind K., Issinger O.G. Structural basis of the constitutive activity of protein kinase CK2. Methods Enzymol. 2010, 484:515-529.
17. Goetz C., Wagner P., Issinger O.G., Montenarh M. p21WAF1/CIP intracts with protein kinase CK2. Oncogene 1996, 13:391-398.
18. Becherel O.J., Jakob B., Cherry A.L., Gueven N., Fusser M., Kijas A.W., Peng C., Katyal S., McKinnon P.J., Chen J., Epe B., Smerdon S.J., Taucher-Scholz G., Lavin M.F. CK2 phosphorylation-dependent interaction between aprataxin and MDC1 in the DNA damage response. Nucleic Acids Res. 2010, 38:1489-1503.
19. Chapman J.R., Jackson S.P. Phospho-dependent interactions between NBS1 and MDC1 mediate chromatin retention of the MRN complex at sites of DNA damage. EMBO Rep. 2008, 9:795-801.
20. Wu L., Luo K., Lou Z., Chen J. MDC1 regulates intra-S-phase checkpoint by targeting NBS1 to DNA double-strand breaks. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11200-11205.
21. Kubota Y., Takanami T., Higashitani A., Horiuchi S. Localization of X-ray cross complementing gene 1 protein in the nuclear matrix is controlled by casein kinase II-dependent phosphorylation in response to oxidative damage. DNA Repair (Amst) 2009, 8:953-960.
22. Luo H., Chan D.W., Yang T., Rodriguez M., Chen B.P., Leng M., Mu J.J., Chen D., Songyang Z., Wang Y., Qin J. A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment. Mol. Cell. Biol. 2004, 24:8356-8365.
23. Parsons J.L., Dianova I.I., Finch D., Tait P.S., Strom C.E., Helleday T., Dianov G.L. XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair. DNA Repair (Amst) 2010, 9:835-841.
24. Zwicker F., Ebert M., Huber P.E., Debus J., Weber K.J. A specific inhibitor of protein kinase CK2 delays gamma-H2Ax foci removal and reduces clonogenic survival of irradiated mammalian cells. Radiat. Oncol. 2011, 6:15.
25. Ayoub N., Jeyasekharan A.D., Bernal J.A., Venkitaraman A.R. HP1-beta mobilization promotes chromatin changes that initiate the DNA damage response. Nature 2008, 453:682-686.
26. Pagano M.A., Andrzejewska M., Ruzzene M., Sarno S., Cesaro L., Bain J., Elliott M., Meggio F., Kazimierczuk Z., Pinna L.A. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J. Med. Chem. 2004, 47:6239-6247.
27. Pagano M.A., Meggio F., Ruzzene M., Andrzejewska M., Kazimierczuk Z., Pinna L.A. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem. Biophys. Res. Commun. 2004, 321:1040-1044.
28. Schneider C.C., Hessenauer A., Gotz C., Montenarh M. DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks. Oncol. Rep. 2009, 21:1593-1597.
29. Fritz G., Issinger O.G., Olsen B.B. Selectivity analysis of protein kinase CK2 inhibitors DMAT, TBB and resorufin in cisplatin-induced stress responses. Int. J. Oncol. 2009, 35:1151-1157.
30. Harper J.W., Elledge S.J. The DNA damage response: ten years after. Mol. Cell. 2007, 28:739-745.
31. Sandholt I.S., Olsen B.B., Guerra B., Issinger O.G. Resorufin: a lead for a new protein kinase CK2 inhibitor. Anticancer Drugs 2009, 20:238-248.